Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Chapman

Showing results (791-800 of 1,011) with videos related to

Pageof 102
Sort By:
Kidney International|March 23, 2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseRon T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 22, 2011
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 StudyVicente E Torres, Esther Meijer, Kyongtae T Bae, et al.
Clinical Pharmacology and Therapeutics|July 3, 2009
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation orderJ A Johnson, Y Gong, K R Bailey, et al.
The Oncologist|February 6, 2023
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant ImmunotherapyThomas M Atkinson, Jennifer L Hay, Soo Young Kim, et al.
Clinical and Translational Science|March 8, 2016
Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?S W Chang, Y Gong, C W McDonough, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanomaDavid B Solit, Iman Osman, David Polsky, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 23, 2013
Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney diseaseKyungsoo Bae, Bumwoo Park, Hongliang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanomaA A Jakubowski, D F Bajorin, M A Templeton, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|April 30, 2015
Psychiatric disorders in children and adolescents 24 months after mild traumatic brain injuryJeffrey E Max, Keren Friedman, Elisabeth A Wilde, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of <i>BRAF</i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
Pageof 102

Showing results (791-800 of 1,011) with videos related to

Sort By:
Pageof 102
Kidney International|March 23, 2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseRon T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 22, 2011
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 StudyVicente E Torres, Esther Meijer, Kyongtae T Bae, et al.
Clinical Pharmacology and Therapeutics|July 3, 2009
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation orderJ A Johnson, Y Gong, K R Bailey, et al.
The Oncologist|February 6, 2023
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant ImmunotherapyThomas M Atkinson, Jennifer L Hay, Soo Young Kim, et al.
Clinical and Translational Science|March 8, 2016
Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?S W Chang, Y Gong, C W McDonough, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanomaDavid B Solit, Iman Osman, David Polsky, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 23, 2013
Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney diseaseKyungsoo Bae, Bumwoo Park, Hongliang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanomaA A Jakubowski, D F Bajorin, M A Templeton, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|April 30, 2015
Psychiatric disorders in children and adolescents 24 months after mild traumatic brain injuryJeffrey E Max, Keren Friedman, Elisabeth A Wilde, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of <i>BRAF</i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
Pageof 102